Clinical Trials Logo

Syndrome clinical trials

View clinical trials related to Syndrome.

Filter by:

NCT ID: NCT04966403 Completed - Down Syndrome Clinical Trials

Effects of Stretch-shortening Cycle Exercises Postural Control in Down Syndrome

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

To investigate the effect of a 3-month, trampoline-based stretch-shortening cycle (SSC) exercises on muscle strength and postural control in children with Down syndrome.

NCT ID: NCT04965636 Recruiting - Clinical trials for Hypereosinophilic Syndrome

Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)

SPHERE
Start date: August 24, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the efficacy and safety of mepolizumab in children and adolescents with hypereosinophilic syndrome (HES) who are receiving standard of care (SoC) therapy.

NCT ID: NCT04965597 Recruiting - Clinical trials for Paroxysmal Nocturnal Hemoglobinuria

Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Start date: April 19, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether treosulfan, fludarabine, and rabbit antithymocyte globulin (rATG) work when given before a blood or bone marrow transplant (conditioning regimen) to cause fewer complications for patients with bone marrow failure diseases. Chemotherapy drugs, such as treosulfan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fludarabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. rATG is used to decrease the body's immune response and may improve bone marrow function and increase blood cell counts. Adding treosulfan to a conditioning regimen with fludarabine and rATG may result in patients having less severe complications after a blood or bone marrow transplant.

NCT ID: NCT04965142 Recruiting - Metabolic Syndrome Clinical Trials

Feasibility of a Home Exercise Program to Manage Post-transplant Metabolic Syndrome

Start date: August 19, 2021
Phase: N/A
Study type: Interventional

Post-transplant metabolic syndrome (PTMS) affects about 50% liver transplant (OLT) and 25% lung transplant (LTx) recipients at 12-18 months post-transplant. PTMS (comprised of glucose intolerance, obesity, hypercholesterolemia and hypertension) has been associated with increased risk for cardiovascular morbidity and long-term survival. Exercise studies in the early post-transplant period have shown some benefits on PTMS risk factors with facility-based training, but it remains unclear if exercise can be sustained in the home environment with sufficient adherence or training intensity to impact PTMS beyond the early post-transplant period. Objectives: 1) To evaluate the feasibility of a three-month individualized, virtual home-based exercise training program in OLT and LTx recipients starting at 1 year post-transplant. 2) To assess estimates of intervention efficacy on elements of PTMS, insulin resistance, exercise self-efficacy, and health related quality of life (HRQL). Methods: 20 OLT and 20 LTx recipients with 2 or more PTMS risk factors at 12-18 months post-transplant will be randomized to a home-based exercise program versus usual care. The exercise group will undergo aerobic training 3 to 5 times per week with resistance training at least twice weekly over a 12-week period. Exercises will be demonstrated by a qualified exercise professional during the first visit with weekly phone and video calls to guide exercise progression, ease communication and promote exercise self-efficacy and adherence based on guiding behavioral principles. As secondary measures, PTMS, insulin resistance, body composition (optional), HRQL, and assessment of self-efficacy will be assessed at baseline and 12-weeks.

NCT ID: NCT04964986 Completed - Clinical trials for Short Bowel Syndrome

Metabolic Balance Study of Apraglutide in Patients With SBS-IF and Colon-in-Continuity

STARSnutrition
Start date: June 14, 2021
Phase: Phase 2
Study type: Interventional

The primary objective of the trial is to evaluate the safety of apraglutide in adult subjects with SBS-IF and CIC.

NCT ID: NCT04961476 Completed - Covid19 Clinical Trials

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19

Start date: January 8, 2021
Phase:
Study type: Observational [Patient Registry]

Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2). Unfortunately, COVID-19 is not only a short-term infection but that patients (pts) recovering from SARS-COV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome. There is currently no evidence that nutritional supplements and/or physical exercise can assist in the recovery of pts with chronic fatigue syndrome. 1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized. 1-MNA demonstrates anti-inflammatory and anti-thrombotic properties. Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-COV-2.

NCT ID: NCT04961281 Completed - Chronic Pain Clinical Trials

Dexmedetomidine Versus Triamcinolone Treatment of Carpal Tunnel Syndrome

Start date: July 22, 2021
Phase: N/A
Study type: Interventional

Carpal tunnel syndrome (CTS) is a common mononeuropathy due to entrapment of the median nerve in the carpal tunnel. a lot of modaleties are available for treatment of mild to moderate CTS.

NCT ID: NCT04960618 Recruiting - Mycosis Fungoides Clinical Trials

Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome

Start date: October 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.

NCT ID: NCT04960605 Completed - Dental Implant Clinical Trials

Prognosis of Dental Implants in Patients With Primary Sjögren's Syndrome

Start date: January 1, 2015
Phase: N/A
Study type: Interventional

Primary Sjögren's Syndrome (PSS) is a chronic autoimmune inflammatory disease primarily involving the salivary and lacrimal glands. Few data exist regarding survival and success rate of dental implants in patients with PSS. Although a previous study suggest lower success rate for dental implants we hypothesize that dental implants have similar survival and success rate in PSS as healthy controls. The purpose of the present study was to evaluate the long-term survival and success rate of dental implants in patients with PSS compared to the healthy controls.

NCT ID: NCT04960592 Active, not recruiting - Chronic Pain Clinical Trials

Epigenetic Mechanisms and Symptom Clusters Associated With Resolution of Pain Following Spinal Cord Stimulation

Start date: February 15, 2021
Phase:
Study type: Observational

Spinal cord stimulation (SCS) is indicated for selected patients with chronic pain who have not responded to conventional medical management. Forty (40) patients indicated for SCS placement and presenting to the University of Arkansas for Medical Sciences (UAMS) Interventional Pain Management Clinic in Little Rock, Arkansas will be recruited for this study. Prior to temporary stimulator placement, patients will complete symptom-related questionnaires and provide a blood sample. Demographic and clinical characteristics will be obtained through medical record review. Patients will complete the same questionnaires and provide a blood sample at each of the routine clinical care follow-up visits.